Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis. [electronic resource]
Producer: 20170406Description: 40-51 p. digitalISSN:- 1095-9157
- Adult
- Antigen Presentation -- immunology
- B-Lymphocyte Subsets -- cytology
- Cell Differentiation -- drug effects
- Cell Survival -- drug effects
- Cytokines -- metabolism
- Female
- Fingolimod Hydrochloride -- pharmacology
- Gene Expression
- Humans
- Immunologic Memory
- Immunophenotyping
- Immunosuppressive Agents -- pharmacology
- Inflammation Mediators -- metabolism
- Interleukin-10 -- biosynthesis
- Leukocyte Count
- Lymphocyte Activation
- Lymphocyte Count
- Male
- Middle Aged
- Multiple Sclerosis -- diagnosis
- Plasma Cells -- immunology
- Receptors, Lysosphingolipid -- genetics
- Sphingosine-1-Phosphate Receptors
- Transforming Growth Factor beta -- biosynthesis
- Young Adult
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.